Apellis Pharmaceuticals, Inc. (APLS)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 178,494 | 166,797 | 196,830 | |
| Selling, general and administrative | 131,139 | 129,345 | 121,984 | |
| Research and development | 67,015 | 86,420 | 88,569 | |
| Cost of sales | 13,626 | 34,360 | 33,557 | |
| Total operating expenses | 211,780 | 250,125 | 244,110 | |
| Net operating loss | -33,286 | -83,328 | -47,280 | |
| Interest income | 2,607 | 2,658 | 2,889 | |
| Interest expense | 11,152 | 11,049 | 12,532 | |
| Other income/(expense), net | 146 | -165 | 70 | |
| Net loss before taxes | -41,685 | -91,884 | -56,853 | |
| Income tax expense | 466 | 341 | 592 | |
| Net loss | -42,151 | -92,225 | -57,445 | |
| Foreign currency translation | 485 | 254 | 222 | |
| Total other comprehensive income | 485 | 254 | 222 | |
| Comprehensive loss, net of tax | -41,666 | -91,971 | -57,223 | |
| Net loss per common share, basic | -0.33 | -0.74 | -0.46 | |
| Net loss per common share, diluted | -0.33 | -0.74 | -0.46 | |
| Weighted-average number of common shares used in net loss per common share, basic | 126,024,000 | 125,453,000 | 124,234,000 | |
| Weighted-average number of common shares used in net loss per common share, diluted | 126,024,000 | 125,453,000 | 124,234,000 | |